Calypte rapid HIV test passes Malaysian government evaluation
US-based healthcare company Calypte Biomedical Corporation has received notification that its rapid blood test for HIV-1 and HIV-2 antibodies, Aware BSP, has been successfully evaluated by government agencies in Malaysia.
US-based healthcare company Calypte Biomedical Corporation has received notification that its rapid blood test for HIV-1 and HIV-2 antibodies, Aware BSP, has been successfully evaluated by government agencies in Malaysia.
Favourable government evaluation is generally requested in Malaysia, although not strictly required to market HIV tests.
Aware BSP is a 20-minute rapid test designed to detect HIV antibodies in whole blood, serum, or plasma. It is one test in a line of three such assays, the other two being designed to detect HIV antibodies in oral fluid and urine.
Malaysia, with a population of roughly 24 million, has an estimated 55,000 HIV infections, according to the CIA Fact book, 2003.